NCT05248230 - 4D-710 in Adult Patients With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2030

Conditions

Cystic Fibrosis Lung

Interventions

BIOLOGICAL

4D-710

4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).

Trial Locations (19)

17033

RECRUITING

Penn State Health, Hershey

19104

RECRUITING

The Hospital of the University of Pennsylvania, Philadelphia

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

23298

RECRUITING

Virginia Commonwealth University Health System, Richmond

27599

ACTIVE_NOT_RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

32610

RECRUITING

University of Florida, Gainesville

33136

RECRUITING

University of Miami Hospital, Miami

35233

RECRUITING

University of Alabama Child Health Research Unit, Birmingham

43205

RECRUITING

Nationwide Children's Hospital, Columbus

44146

RECRUITING

Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland

60611

RECRUITING

Northwestern Memorial Hospital, Chicago

66160

RECRUITING

University of Kansas Medical Center, Kansas City

75390

RECRUITING

The University of Texas Southwestern Medical Center, Dallas

80206

RECRUITING

National Jewish Health, Denver

85724

RECRUITING

The University of Arizona, Tucson

94143

RECRUITING

University of California San Francisco, San Francisco

98195

RECRUITING

University of Washington Medical Center, Seattle

02114

RECRUITING

Massachusetts General Hospital, Boston

02115

RECRUITING

Boston Children's Hospital, Boston